Primary Biliary Cholangitis Global Market Report 2025
상품코드:1825522
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
원발성 담즙성 담관염 시장의 규모는 앞으로 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 8.6%로 14억 7,000만 달러로 성장할 전망입니다. 예측기간의 성장은 바이오마커 연구의 확대, 희소질환 관리의 세계적인 노력, 임상시험에서의 협력체제의 강화, 환자 중심의 헬스케어 접근, 간이식 수요 증가 등에 기인할 것으로 전망됩니다. 예측기간의 주요 동향으로는 바이오마커 연구의 진전, 비침습적 진단기술의 중시 증가, 면역조절요법에 대한 연구의 주력, 인공지능(AI)의 통합, 임상시험에서의 환자보고 결과, 환자관리를 위한 원격의료, 병용요법의 중시, 섬유증을 표적으로 한 새로운 치료법 등을 들 수 있습니다.
향후 5년간의 예측 성장률 8.6%는 이 시장에 관한 과거 예측에서 0.3% 소폭 감소한 수치입니다. 이러한 성장세 둔화는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세의 부과는 스페인과 폴란드에서 수입되는 우르소데옥시콜산(UDCA)과 오베티콜산의 비용을 증가시키고, 치료 개시를 지연시키거나, 간질환 클리닉의 비용을 증가시킬 수 있기 때문에 미국의 치료 접근을 혼란시킬 수 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 예상됩니다.
흡연 증가가 예상되면서 앞으로 수년간 원발성 담즙성 담관염 시장의 확대를 견인할 것으로 보입니다. 흡연은 담배 및 기타 물질의 연소로 인한 연기의 흡입과 호기를 수반합니다. 흡연은 PBC를 포함한 간질환의 위험 인자로 인식되고 있으며, 흡연률 증가는 간 관련 문제로 진단받는 인구의 증가를 초래할 수 있습니다. 예를 들어, 2023년 7월 캐나다 통계국은 2023년 6월에 비해 2.2%의 담배 생산량 증가를 보고했으며, 이에 해당하는 담배 판매량도 2.6% 증가했으며, 6월은 5월에 비해 14억갑에 달했습니다. 따라서 흡연 증가는 원발성 담즙성 담관염 시장의 성장을 가속할 것으로 예측됩니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 원발성 담즙성 담관염 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 원발성 담즙성 담관염 시장 : 성장률 분석
세계의 원발성 담즙성 담관염 시장 실적 : 규모와 성장(2019-2024년)
세계의 원발성 담즙성 담관염 시장 예측 : 규모와 성장(2024-2029년, 2034F)
세계의 원발성 담즙성 담관염 : 총 시장 규모(TAM)
제6장 시장 세분화
세계의 원발성 담즙성 담관염 시장 : 치료 유형별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
약물
간 이식
세계의 원발성 담즙성 담관염 시장 : 진단별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
화상 검사
자기 공명 엘라스토그래피(MRE)
자기 공명 담도 췌관 조영(MRCP)
초음파
피브로 스캔
혈액검사
콜레스테롤 검사
항체 검사
간검사
기타 진단
세계의 원발성 담즙성 담관염 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
전문 클리닉
가정
기타 최종 사용자
세계의 원발성 담즙성 담관염 시장 : 세분화 약물(유형별), 분석과 예측(2019-2024년, 2024-2029F, 2034F)
우르소데옥시콜산(UDCA)
오베티콜산(OCA)
피브레이트
면역억제제
기타 표적요법
세계의 원발성 담즙성 담관염 시장 : 세분화 간 이식(유형별), 분석과 예측(2019-2024년, 2024-2029F, 2034F)
동소성 간이식(OLT)
생체 간 이식
간 이식을 위한 간담도 수술
제7장 지역별/국가별 분석
세계의 원발성 담즙성 담관염 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
세계의 원발성 담즙성 담관염 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
원발성 담즙성 담관염 시장 : 경쟁 구도
원발성 담즙성 담관염 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
F. Hoffmann-La Roche Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck And Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Bristol-Myers Squibb Company : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
AstraZeneca plc
GlaxoSmithKline plc
Takeda Pharmaceutical Company
Amgen Inc.
Boehringer Ingelheim International GmbH.
Gilead Sciences Inc.
Vertex Pharmaceuticals
Dr. Reddy's Laboratories Ltd.
Amneal Pharmaceuticals LLC
Alnylam Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc.
Intercept Pharmaceuticals Inc
Arrowhead Pharmaceuticals Inc.
CureVac NV
Sangamo Therapeutics Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
원발성 담즙성 담관염 시장(2029년) : 새로운 기회를 제공하는 국가
원발성 담즙성 담관염 시장(2029년) : 새로운 기회를 제공하는 부문
원발성 담즙성 담관염 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
CSM
영문 목차
영문목차
Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by the progressive inflammation and destruction of the small bile ducts within the liver. This condition can lead to impaired bile flow, liver damage, and various related complications. PBC primarily affects middle-aged women and is often associated with symptoms such as fatigue, itching, and abdominal discomfort.
The main types of treatment for primary biliary cholangitis are drugs and liver transplantation. A drug is any chemical substance that causes a change in an organism's physiology or psychology when consumed, and ursodeoxycholic acid (UDCA) is the standard first-line treatment for PBC. UDCA helps improve liver function, reduce liver inflammation, and slow down disease progression. Primary biliary cholangitis is diagnosed through various imaging tests such as magnetic resonance elastography (MRE), magnetic resonance cholangiopancreatography (MRCP), ultrasound, fibroscan, as well as blood tests including cholesterol tests, antibody tests, and liver function tests. These diagnostic methods are employed by end-users such as specialty clinics, homecare services, and other healthcare facilities.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The primary biliary cholangitis market research report is one of a series of new reports from The Business Research Company that provides primary biliary cholangitis market statistics, including primary biliary cholangitis industry global market size, regional shares, competitors with a primary biliary cholangitis market share, detailed primary biliary cholangitis market segments, market trends and opportunities, and any further data you may need to thrive in the primary biliary cholangitis industry. This primary biliary cholangitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The primary biliary cholangitis market size has grown strongly in recent years. It will grow from $0.98 billion in 2024 to $1.06 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to increased disease awareness, rising global healthcare expenditure, strategic collaborations in the healthcare sector, focus on patient advocacy, government initiatives for liver health.
The primary biliary cholangitis market size is expected to see strong growth in the next few years. It will grow to $1.47 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to expansion of biomarker research, global efforts in rare disease management, increased collaboration in clinical trials, patient-centric healthcare approaches, rising demand for liver transplants. Major trends in the forecast period include advancements in biomarker research, growing emphasis on non-invasive diagnostic techniques, research focus on immunomodulatory therapies, integration of artificial intelligence (AI), patient-reported outcomes in clinical trials, telemedicine for patient management, focus on combination therapies, emerging therapies targeting fibrosis.
The forecast of 8.6% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. treatment access by increasing costs for ursodeoxycholic acid (UDCA) and obeticholic acid imported from Spain and Poland, potentially delaying therapy initiation and raising hepatology clinic expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The anticipated rise in smoking is poised to drive the expansion of the primary biliary cholangitis market in the coming years. Smoking involves the inhalation and exhalation of smoke generated by burning tobacco or other substances. It is a recognized risk factor for liver diseases, including PBC, and elevated smoking rates may result in an increased number of individuals seeking medical attention for liver-related issues. As an illustration, in July 2023, Statistics Canada reported a 2.2% increase in cigarette production compared to June 2023, with a corresponding 2.6% rise in cigarette sales, reaching 1.4 billion units in June compared to May. Consequently, the upswing in smoking is expected to propel the primary biliary cholangitis market's growth.
The rise in liver cancer is expected to drive the growth of the primary biliary cholangitis market in the future. Liver cancer, also known as hepatocellular carcinoma, is a type of cancer that begins in the liver cells. Primary biliary cholangitis plays a significant role in liver cancer due to the increased risk of various malignancies, including cholangiocarcinoma and hepatocellular carcinoma. The growing prevalence of this disease and its potential complications are contributing to the expansion of the primary biliary cholangitis market. For example, in January 2024, the American Cancer Society, a leading professional organization in the U.S., projected approximately 41,630 new cases of liver cancer in the country, with 28,000 cases in men and 13,630 in women. Additionally, about 29,840 individuals (19,120 men and 10,720 women) are expected to die from the disease. As a result, the increase in liver cancer cases is driving the growth of the primary biliary cholangitis market.
Major companies operating in the primary biliary cholangitis market are directing their efforts towards the development of innovative and specialized treatments. This includes the creation of orphan drugs featuring a combination of obeticholic acid (OCA) and bezafibrates for the treatment of primary biliary cholangitis (PBC), aiming to secure market exclusivity. The combination of OCA and bezafibrate, with an orphan drug designation, seeks to provide a more comprehensive and effective approach to managing PBC treatment, potentially enhancing the quality of life for individuals affected by this rare condition. For example, in May 2023, Intercept Pharmaceuticals, Inc., a US-based biopharmaceutical company, obtained orphan drug designation from the FDA for the combination of obeticholic acid (OCA) and bezafibrate as a potential treatment for PBC, a progressive liver disease, with OCA already approved for PBC in the US.
In March 2023, Ipsen SA, a France-based pharmaceutical company, completed the acquisition of Albireo Pharma, Inc. for an undisclosed amount. This strategic move by Ipsen aims to broaden its rare disease portfolio by incorporating novel pipeline prospects, promising therapies for rare cholestatic liver diseases in both children and adults, and leveraging strong scientific and commercial capabilities. Albireo Pharma Inc., a US-based biopharmaceutical company, is actively developing A3907 therapy for primary biliary cholangitis (PBC), contributing to Ipsen's expansion in the rare disease segment.
Major companies operating in the primary biliary cholangitis market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Amgen Inc., Boehringer Ingelheim International GmbH., Gilead Sciences Inc., Vertex Pharmaceuticals, Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals LLC, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Intercept Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., CureVac N.V., Sangamo Therapeutics Inc., Calliditas Therapeutics AB, NGM Biopharmaceuticals Inc., Bluebird Bio Inc., Intellia Therapeutics Inc., Albireo Pharma Inc., TARGET PharmaSolutions Inc., Genfit S.A., Editas Medicine Inc., CymaBay Therapeutics Inc., Ascletis Pharma Inc.
North America was the largest region in the primary biliary cholangitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the primary biliary cholangitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary biliary cholangitis market includes revenues earned by entities by providing services such as psychosocial support services, nutritional guidance services, medical diagnosis, and specialized medical care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The primary biliary cholangitis market also includes sales of products such as fat-soluble vitamins, anti-itch medications, and imaging equipment. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Primary Biliary Cholangitis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on primary biliary cholangitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for primary biliary cholangitis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The primary biliary cholangitis market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Treatment Type: Drugs; Liver Transplantation
2) By Diagnosis: Imaging Tests; Magnetic Resonance Elastography (MRE); Magnetic Resonance Cholangiopancreatography (MRCP); Ultrasound; Fibroscan; Blood Tests; Cholesterol Test; Antibody Tests; Liver Tests; Other Diagnoses
3) By End-Users: Specialty Clinics; Homecare; Other End-Users
Subsegments:
1) By Drugs: Ursodeoxycholic Acid (UDCA); Obeticholic Acid (OCA); Fibrates; Immunosuppressive Drugs; Other Targeted Therapies
2) By Liver Transplantation: Orthotopic Liver Transplantation (OLT); Living Donor Liver Transplantation; Hepatobiliary Surgery For Liver Transplant
3. Primary Biliary Cholangitis Market Trends And Strategies
4. Primary Biliary Cholangitis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Primary Biliary Cholangitis Growth Analysis And Strategic Analysis Framework
5.1. Global Primary Biliary Cholangitis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Primary Biliary Cholangitis Market Growth Rate Analysis
5.4. Global Primary Biliary Cholangitis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Primary Biliary Cholangitis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Primary Biliary Cholangitis Total Addressable Market (TAM)
6.1. Global Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Drugs
Liver Transplantation
6.2. Global Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Imaging Tests
Magnetic Resonance Elastography (MRE)
Magnetic Resonance Cholangiopancreatography (MRCP)
Ultrasound
Fibroscan
Blood Tests
Cholesterol Test
Antibody Tests
Liver Tests
Other Diagnoses
6.3. Global Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Specialty Clinics
Homecare
Other End-Users
6.4. Global Primary Biliary Cholangitis Market, Sub-Segmentation Of Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Ursodeoxycholic Acid (UDCA)
Obeticholic Acid (OCA)
Fibrates
Immunosuppressive Drugs
Other Targeted Therapies
6.5. Global Primary Biliary Cholangitis Market, Sub-Segmentation Of Liver Transplantation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Orthotopic Liver Transplantation (OLT)
Living Donor Liver Transplantation
Hepatobiliary Surgery For Liver Transplant
7. Primary Biliary Cholangitis Market Regional And Country Analysis
7.1. Global Primary Biliary Cholangitis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Primary Biliary Cholangitis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Primary Biliary Cholangitis Market
9.1. China Primary Biliary Cholangitis Market Overview
9.2. China Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Primary Biliary Cholangitis Market
10.1. India Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Primary Biliary Cholangitis Market
11.1. Japan Primary Biliary Cholangitis Market Overview
11.2. Japan Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Primary Biliary Cholangitis Market
12.1. Australia Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Primary Biliary Cholangitis Market
13.1. Indonesia Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Primary Biliary Cholangitis Market
14.1. South Korea Primary Biliary Cholangitis Market Overview
14.2. South Korea Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Primary Biliary Cholangitis Market
15.1. Western Europe Primary Biliary Cholangitis Market Overview
15.2. Western Europe Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Primary Biliary Cholangitis Market
16.1. UK Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Primary Biliary Cholangitis Market
17.1. Germany Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Primary Biliary Cholangitis Market
18.1. France Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Primary Biliary Cholangitis Market
19.1. Italy Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Primary Biliary Cholangitis Market
20.1. Spain Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Primary Biliary Cholangitis Market
21.1. Eastern Europe Primary Biliary Cholangitis Market Overview
21.2. Eastern Europe Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Primary Biliary Cholangitis Market
22.1. Russia Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Primary Biliary Cholangitis Market
23.1. North America Primary Biliary Cholangitis Market Overview
23.2. North America Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Primary Biliary Cholangitis Market
24.1. USA Primary Biliary Cholangitis Market Overview
24.2. USA Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
